Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Abbvie
Pharmaceutical Preparation ManufacturingUnited StatesNYSE: ABBV
Last verified 9 months agoabbvie.com
AbbVie Inc., commonly known as AbbVie, is a global biopharmaceutical company with its headquarters located in the United States. Established in 2013 following its separation from Abbott Laboratories, it operates within the pharmaceutical preparation manufacturing industry. AbbVie is dedicated to the research, development, and commercialisation of advanced therapeutic solutions.
The company focuses on addressing some of the world's most complex and serious diseases across key therapeutic areas such as immunology, oncology, and neuroscience. Its extensive portfolio includes innovative medicines and treatments like Humira, Skyrizi, Rinvoq, and Botox, demonstrating a commitment to scientific innovation.
AbbVie holds a significant market position, striving to deliver breakthrough therapies that have a remarkable impact on patient care globally. Through relentless scientific inquiry and development, AbbVie aims to improve health outcomes and quality of life for millions of individuals.
56
DitchCarbon score
+14 vs industry average
Abbvie’s score of 56 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Abbvie?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Abbvie's reported carbon emissions
AbbVie, a US-based pharmaceutical preparation manufacturing company, reported its Scope 1 emissions for 2025 as approximately 304,649,000 kg CO2e and its market-based Scope 2 emissions as about 76,201,000 kg CO2e. For 2024, its Scope 1 emissions were around 300,072,000 kg CO2e and market-based Scope 2 emissions were approximately 122,287,000 kg CO2e. In 2023, the company's Scope 1 emissions stood at roughly 328,259,000 kg CO2e, with market-based Scope 2 emissions at about 131,232,000 kg CO2e.
AbbVie has committed to reducing absolute Scope 1 and 2 GHG emissions by 42.0% by 2030, using a 2021 base year. This target is validated by the Science Based Targets initiative (SBTi) as consistent with keeping global warming to 1.5°C. Furthermore, the company aims to increase its active sourcing of renewable electricity from 29.5% in 2021 to 100.0% by 2030. AbbVie also has a long-term ambition to achieve net-zero emissions by 2050. Additionally, AbbVie commits that 79.1% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027.
Assessing Abbvie as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Abbvie and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Abbvie’s Climate Goals (2030 & 2050)
2 goals2030
42% reduction in Scope 2
AbbVie commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2021 base year*. *The target boundary includes land-relat…
On track42%
2030
42% reduction in Scope 1
AbbVie commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2021 base year*. *The target boundary includes land-relat…
Behind target42%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
2030 targetSee details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Abbvie9 months ago
56
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Abbvie’s sustainability data and climate commitments
AbbVie, a US-based pharmaceutical company, reported its total market-based Scope 1 and 2 emissions for 2025 as approximately 380,850,000 kg CO2e. Looking at the breakdown for 2025, Scope 1 emissions were about 304,649,000 kg CO2e, while market-based Scope 2 emissions were roughly 76,201,000 kg CO2e. The company has consistently disclosed its Scope 1 and 2 emissions, providing a clear picture of its operational carbon footprint.
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more